Literature DB >> 10779754

Crry/p65, a membrane complement regulatory protein, has costimulatory properties on mouse T cells.

E Fernández-Centeno1, G de Ojeda, J M Rojo, P Portolés.   

Abstract

It is known that certain type I membrane molecules (complement receptors type 1 and 2) belonging to the regulators of complement activation (RCA) family are involved in the regulation of B lymphocyte activation. In contrast, only GPI-anchored RCA molecules (CD55) have been described to be involved in T lymphocyte activation. In this study, we describe a novel function for the mouse RCA type I membrane protein Crry/p65 as a costimulatory molecule in CD4+ T cell activation. This is shown by increased anti-CD3-induced proliferation of CD4+ spleen T lymphocytes in the presence of the Crry/p65-specific mAb P3D2. Furthermore, Ab-induced coligation of Crry/p65 and CD3 favors IL-4 rather than IFN-gamma secretion in these cells. Crry/p65 signaling was also observed regardless of additional Ca2+, protein kinase C, or CD28-mediated costimuli. Analysis of intracellular intermediaries shows that Crry/p65-CD3 coligation enhances certain TCR/CD3-mediated signals, producing increased early tyrosine phosphorylation of many substrates and enhanced activation of the mitogen-activated protein kinase, extracellular signal-related kinase. These data fit well with the association of Crry/p65 with the tyrosine kinase Lck found in T cell lysates. The epitope recognized by the mAb P3D2 interferes with the protective role of Crry/p65 on C3 deposition. The relationship between protective function and costimulation by Crry/p65 is discussed. Our results support a multifunctional role for Crry/p65 in T cells and suggest new links between the natural and adaptive immune responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779754     DOI: 10.4049/jimmunol.164.9.4533

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  The effect of locally synthesised complement on acute renal allograft rejection.

Authors:  Steven Sacks; Wuding Zhou
Journal:  J Mol Med (Berl)       Date:  2003-06-25       Impact factor: 4.599

Review 2.  CD46 processing: a means of expression.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Immunobiology       Date:  2011-07-13       Impact factor: 3.144

Review 3.  Complement system in lung disease.

Authors:  Pankita H Pandya; David S Wilkes
Journal:  Am J Respir Cell Mol Biol       Date:  2014-10       Impact factor: 6.914

Review 4.  CD46 plasticity and its inflammatory bias in multiple sclerosis.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-01-26       Impact factor: 4.291

Review 5.  Complement and the Regulation of T Cell Responses.

Authors:  Erin E West; Martin Kolev; Claudia Kemper
Journal:  Annu Rev Immunol       Date:  2018-04-26       Impact factor: 28.527

6.  Expression of complement components and regulators by different subtypes of bone marrow-derived macrophages.

Authors:  Chang Luo; Mei Chen; Angelina Madden; Heping Xu
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

7.  An allelic variant of Crry in the murine Sle1c lupus susceptibility interval is not impaired in its ability to regulate complement activation.

Authors:  Svetlana N Tchepeleva; Joshua M Thurman; Katherine Ruff; Stephen J Perkins; Laurence Morel; Susan A Boackle
Journal:  J Immunol       Date:  2010-07-21       Impact factor: 5.422

Review 8.  T-cell regulation by CD46 and its relevance in multiple sclerosis.

Authors:  Anne L Astier
Journal:  Immunology       Date:  2008-04-02       Impact factor: 7.397

9.  T cell activation by soluble C1q-bearing immune complexes: implications for the pathogenesis of rheumatoid arthritis.

Authors:  K Jiang; Y Chen; C-S Xu; J N Jarvis
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

10.  Abnormal Tr1 differentiation in multiple sclerosis.

Authors:  Anne L Astier; David A Hafler
Journal:  J Neuroimmunol       Date:  2007-10-22       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.